Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with
recurrent glioblastoma multiforme or gliosarcoma.